
Royalcare Super Speciality Hospitals
vs. prev. close ₹160
52W High
₹160
52W Low
₹125
Market cap
₹3,176 Cr
IPO stage
No DRHP filed
CIN
U85100TZ2012PLC018984
Price History
52W High
₹160
52W Low
₹125
About Royalcare Super Speciality Hospitals
RoyalCare Super Speciality Hospital Limited, a Coimbatore-based multi-disciplinary hospital, grew FY26 revenue 25.75% to Rs 448.90 crore and PAT 175.45% to Rs 26.11 crore (EPS Rs 1.33, ROE 5.80%), with Book Value per Share rising to Rs 21.99 amid continued capacity expansion and a proposed Rs 0.20 per share dividend.
The Short Version :
RoyalCare Super Speciality Hospital Limited, based in Coimbatore, Tamil Nadu, operates a super speciality hospital offering multi-disciplinary healthcare services. FY26 revenue from operations grew 25.75% to Rs 448.90 crore from Rs 356.99 crore, with PAT up 175.45% to Rs 26.11 crore from Rs 9.48 crore. EPS (Basic and Diluted) came in at Rs 1.33 versus Rs 0.53 a year earlier, with ROE at 5.80% (up from 3.00%) and Book Value per Share of Rs 21.99, up from Rs 15.43. The Board has recommended a final dividend of Rs 0.20 per equity share for FY26.
Why It Trades Where It Does :
RoyalCare's case is margin expansion alongside strong growth: PAT growth (175.45%) far outpaced revenue growth (25.75%), pointing to real operating leverage as the hospital's fixed cost base (facilities, doctors, equipment) is spread across a larger revenue base. Finance costs actually fell 27.28% even as the balance sheet grew substantially, Property, Plant & Equipment nearly doubled to Rs 610.80 crore, alongside continued Capital Work in Progress of Rs 300.92 crore, consistent with an active capacity expansion. Total Equity grew 42.44% to Rs 450.50 crore, aided by fresh equity share capital raised during the year (Rs 188.66 crore to Rs 204.91 crore). ROE at 5.80%, while improved, remains modest relative to the scale of capital deployed, typical of a hospital business still absorbing a large capex cycle.
Top Risks :
The company is proposing to issue Equity Shares with Differential Voting Rights (DVR) carrying 74% of total voting power on just a 10.50% economic stake, a governance structure that would concentrate control well beyond the promoters' equity ownership.
ROE of 5.80%, while improving, remains modest relative to the scale of capital deployed (Rs 450.50 crore of equity, Rs 552.50 crore of borrowings), reflecting a business still absorbing a large capex cycle.
As a single-hospital healthcare provider, revenue is concentrated in one facility and geography (Coimbatore), without the diversification of a multi-hospital chain.
Top Opportunities :
PAT growth (175.45%) far outpacing revenue growth (25.75%) shows the hospital scaling profitably as recent capacity investments mature.
Continued heavy capex (Capital Work in Progress of Rs 300.92 crore) signals further capacity expansion ahead, a potential driver of future revenue growth.
A maintained dividend payout alongside strong profit growth signals management's confidence in sustaining returns to shareholders through the expansion phase.
Disclaimer :
Priveq.in is an informational platform for unlisted and pre-IPO shares, operated by Priveq Investech Private Limited (the named counterparty on transactions). Unlisted shares carry risks including illiquidity, valuation uncertainty, and limited regulatory disclosure. This page is informational only and does not constitute investment advice.
Company Details
Industry
Healthcare & Hospitals
Founded
2015
Headquarters
Coimbatore, Tamil Nadu, India
Min Lot Size
100
Face Value
₹10.00
Total Shares
204908478
Regulatory Information
Corporate Identity Number (CIN)
U85100TZ2012PLC018984
PAN Number
AAGCR1968R
ISIN
INE02C801010
Key Valuation Ratios
Valuation
Market Cap
₹3,176.08 Cr
P/E Ratio
121.64×
P/S Ratio
7.08×
P/B Ratio
7.05×
EV / EBITDA
44.69×
Returns & Per Share
ROE
5.80%
EPS
₹1.27
Book Value / Share
₹21.99
Solvency
Debt / Equity
1.23×
Interest Coverage
3.08×
Company Fundamentals
As of FY2026 Annual · updated 25 Sept 2026Gross Profit
₹351.20 Cr
EBITDA
₹83.12 Cr
Revenue Growth
25.75%
Profit Margin
5.82%
Performance Trends
5 annual periods · derived from filed statements
Revenue
₹ Cr
Net Profit
₹ Cr · losses in red
Earnings Per Share
₹ per share
Return on Equity
ROE %
Return on Capital Employed
ROCE %
Debt-to-Equity
1.23×
EBITDA Margin
18.52%
Interest Coverage
3.08×
Financial Statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total Income | |||||
| Revenue from operationsDisclosed | 301.15₹ Crore | 305.49₹ Crore | 332.73₹ Crore | 356.99₹ Crore | 448.9₹ Crore |
| Other incomeDisclosed | 4.22₹ Crore | 5.16₹ Crore | 5.19₹ Crore | 4.33₹ Crore | 5.92₹ Crore |
| Total IncomeDerived | 305.37₹ Crore | 310.65₹ Crore | 337.92₹ Crore | 361.32₹ Crore | 454.82₹ Crore |
| Expenses | |||||
| Cost of goods soldDisclosed | 71.23₹ Crore | 68.57₹ Crore | 72.76₹ Crore | 73.45₹ Crore | 97.7₹ Crore |
| Purchases of stock-in-tradeDisclosed | 26.16₹ Crore | 29.81₹ Crore | 33.66₹ Crore | 34.31₹ Crore | 41.7₹ Crore |
| Changes in inventoriesDisclosed | -32₹ Lakh | -27₹ Lakh | -1.95₹ Crore | 1.18₹ Crore | 0₹ Crore |
| Employee benefits expenseDisclosed | 52.54₹ Crore | 53.8₹ Crore | 54.09₹ Crore | 64.86₹ Crore | 79.85₹ Crore |
| Finance costsDisclosed | 27.17₹ Crore | 26.84₹ Crore | 22.15₹ Crore | 22.24₹ Crore | 16.17₹ Crore |
| Depreciation and amortization expenseDisclosed | 23.72₹ Crore | 24.39₹ Crore | 24.53₹ Crore | 34.36₹ Crore | 33.34₹ Crore |
| Manufacturing expensesDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Operating expensesDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Other expensesDisclosed | 83.55₹ Crore | 91.95₹ Crore | 108.36₹ Crore | 117.44₹ Crore | 152.45₹ Crore |
| Total ExpensesDerived | 284.05₹ Crore | 295.09₹ Crore | 313.6₹ Crore | 347.84₹ Crore | 421.21₹ Crore |
| Profit | |||||
| Exceptional itemsDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Profit before taxDerived | 21.32₹ Crore | 15.56₹ Crore | 24.32₹ Crore | 13.48₹ Crore | 33.61₹ Crore |
| Current tax expenseDisclosed | 9₹ Lakh | -12₹ Lakh | -16₹ Lakh | 4₹ Crore | 7.5₹ Crore |
| Deferred tax expenseDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Tax expenseDisclosed | 9₹ Lakh | -12₹ Lakh | -16₹ Lakh | 4₹ Crore | 7.5₹ Crore |
| Profit After TaxDerived | 21.23₹ Crore | 15.68₹ Crore | 24.48₹ Crore | 9.48₹ Crore | 26.11₹ Crore |
| Other comprehensive incomeDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 24₹ Lakh | 54₹ Lakh |
| Total Comprehensive IncomeDerived | 21.23₹ Crore | 15.68₹ Crore | 24.48₹ Crore | 9.72₹ Crore | 26.65₹ Crore |
Dr. K. Madeswaran
Chairman & MD
25+
Dr. K. Chockalingam
Director
25+
Sri. T.Balachander
Director & CFO
25+
EGM of Royalcare Hospital for Private Placement others Company is seeking shareholder approval to issue up to 6 crore equity shares via private placement to raise funds.
EGM of Royalcare Hospital for Private Placement others Company is seeking shareholder approval to issue up to 6 crore equity shares via private placement to raise funds.
Express buy interest
No commitment — the desk will reach out
Current Price
₹155Secure & Verified Transaction
Unlisted shares are illiquid and carry higher market risks. Please read the Risk Disclosure before investing.
Talk to a Specialist
Get expert guidance on this investment
About Royalcare Super Speciality Hospitals unlisted shares
Indicative · updated dailyRoyalcare Super Speciality Hospitals unlisted share price today
Royalcare Super Speciality Hospitals unlisted share price today is ₹155 as of 16 October 2026.
Royalcare Super Speciality Hospitals — frequently asked questions
- What is the grey market price for Royalcare Super Speciality Hospitals?
No IPO is currently announced for Royalcare Super Speciality Hospitals, so no grey market exists; the price above reflects Priveq's own desk valuation.
- Has Royalcare Super Speciality Hospitals filed for an IPO, and when might it list?
Royalcare Super Speciality Hospitals has not filed a draft red herring prospectus, so no IPO is currently announced and no listing date has been set.
- How does Royalcare Super Speciality Hospitals compare to its listed peers?
There is no closely comparable listed company for Royalcare Super Speciality Hospitals in India today.
- Is Royalcare Super Speciality Hospitals on the SME or Mainboard IPO track?
Royalcare Super Speciality Hospitals has not filed a draft red herring prospectus, so no IPO track is set yet.
- What is Royalcare Super Speciality Hospitals's CIN and registered office?
Royalcare Super Speciality Hospitals's Corporate Identity Number is U85100TZ2012PLC018984, registered at Coimbatore, Tamil Nadu, India.
- What is Royalcare Super Speciality Hospitals's market capitalisation?
Royalcare Super Speciality Hospitals's market capitalisation is approximately ₹3,176 crore, based on its current unlisted share price.
More in Healthcare & Hospitals
All Healthcare & Hospitals →Buying, selling and holding unlisted shares
Applies to every company on Priveq- How do I buy Royalcare Super Speciality Hospitals unlisted shares?
Priveq Investech Private Limited is the named counterparty on every transaction. To buy Royalcare Super Speciality Hospitals unlisted shares: complete KYC once (PAN, Aadhaar, bank details, and demat account information — SEBI-compliant, typically approved within 24 hours), then submit your order through your Priveq dashboard specifying quantity. Our team confirms price and payment details with you directly. Once payment is confirmed, Royalcare Super Speciality Hospitals shares are transferred off-market straight to your demat account, with no pooling and no middlemen.
- How do I sell Royalcare Super Speciality Hospitals unlisted shares?
Submit an Express Sell Interest for Royalcare Super Speciality Hospitals through your Priveq dashboard, specifying quantity, the same way a buy order is placed. Priveq quotes you a bid price, which may differ from the live Buy price shown to buyers, since unlisted-share pricing works on a bid-ask basis rather than a single quote. Once you accept, you'll need to provide your Client Master List (CML), a cancelled cheque or bank details, and PAN. If you hold shares with CDSL, transfer can also be completed digitally via CDSL Easiest. You transfer Royalcare Super Speciality Hospitals shares to Priveq first, and payment follows once the transfer is confirmed received, typically the same day, T+1, or occasionally T+2, communicated to you directly. For sizeable transactions worth crores of rupees, an escrow arrangement can be used instead, at the sole consent of both parties.
- What is the minimum investment for Royalcare Super Speciality Hospitals unlisted shares?
Minimum investment varies by company and is shown as the Min Investment figure on this page. Royalcare Super Speciality Hospitals's minimum is ₹15,500.
- Is there a maximum investment limit?
There's no fixed maximum investment limit for Royalcare Super Speciality Hospitals unlisted shares. For sizeable transactions worth crores of rupees, an escrow arrangement can be used at the sole consent of both parties, the same mechanism available on the sell side.
- Is buying Royalcare Super Speciality Hospitals unlisted shares legal in India?
Yes. Buying and selling unlisted shares in India is legal and is subject to relevant SEBI regulations, including the mandatory lock-in period after listing, stamp duty, and depository participant charges on each transaction. Priveq's own KYC process is built to be SEBI-compliant.
- What is the lock-in period for Royalcare Super Speciality Hospitals unlisted shares?
Royalcare Super Speciality Hospitals has not filed a DRHP yet, so no listing date or lock-in period applies at this stage. Once an IPO is filed, this answer updates to reflect the applicable SME or Mainboard lock-in.
- What happens if Royalcare Super Speciality Hospitals's IPO is delayed or withdrawn?
If an IPO is delayed, shares remain unlisted and continue to trade on the desk at Priveq's indicative price, with no lock-in in effect until an actual listing happens. If a company formally withdraws its DRHP, the same applies: shares stay unlisted, with no lock-in period until and unless a fresh IPO process begins.
- How are capital gains on Royalcare Super Speciality Hospitals unlisted shares taxed?
If you sell unlisted shares, including Royalcare Super Speciality Hospitals, within 24 months of purchase, the gain is taxed as short-term capital gain at your applicable income tax slab rate. Beyond 24 months, it is taxed as long-term capital gain at 12.5 percent, without indexation benefit, under the rules effective from 23 July 2024. If Royalcare Super Speciality Hospitals lists and you sell after listing, the applicable tax treatment shifts to listed-security rates, with the holding period still measured from your original unlisted purchase date. This is general information, not tax advice; investors should confirm their specific position with a tax advisor.
- Can NRIs invest in Royalcare Super Speciality Hospitals unlisted shares?
Yes, on a non-repatriable basis. NRIs can invest using funds from an NRO account; sale proceeds stay within India unless repatriated separately under RBI's own limits. Priveq does not currently support repatriable investment (NRE/FCNR-funded), which would require the investee company to file additional RBI paperwork as foreign direct investment.
- Does Priveq charge a platform fee on top of the share price?
No. The price quoted to you is all-in; there is no separate platform fee or brokerage added on top.
- How does Priveq determine the desk price for Royalcare Super Speciality Hospitals?
Priveq's desk price reflects several inputs together, not a single formula: the seller's ask price at the time, current demand and supply on the platform for Royalcare Super Speciality Hospitals specifically, broader sentiment in the unlisted and pre-IPO market, how Royalcare Super Speciality Hospitals's sector and listed peers are trading, the company's own recent financial performance and IPO-stage developments, and recent transaction history where deals have actually closed.
Because unlisted shares trade over the counter rather than on an exchange, this price is indicative, not a continuously live quoted market price, and the actual deal price is confirmed with you directly before a transaction closes.
- Is Priveq SEBI-registered? Does it give investment advice?
Priveq is not a SEBI-registered stock exchange and not a SEBI-registered investment adviser. Priveq Investech Private Limited operates Priveq.in as a research and information platform for unlisted and pre-IPO shares, and is the named counterparty on transactions executed through the platform. Nothing on this page is investment advice; it's information to help you evaluate a company and decide for yourself.
- Am I eligible to invest through Priveq if I'm not an HNI?
Yes. Priveq isn't a stock exchange with membership restrictions, and investing isn't limited to HNIs. Depending on the company, entry points can start as low as ₹20,000, though the minimum for any specific company is shown as the Min Investment figure on its page.
- What documents do I receive after buying unlisted shares?
You receive an email acknowledging and confirming your order, along with a deal note or invoice recording the transaction details.
- What happens to my shares or money if a deal falls through?
Because Priveq is the direct counterparty on every transaction rather than just connecting a buyer and seller, this risk sits with Priveq, not with you. If a deal falls through after you've committed funds or shares, they remain safe, and Priveq guarantees a refund.